Clinical Overview of B7-33

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

B7-33 is a synthetic therapeutic candidate initially developed at Monash University, Australia. Its design was based on targeting relaxin receptor 1 (RXFP1), a G-protein-coupled receptor with promising implications in cardiovascular and renal disorders. Preclinical investigations have demonstrated the compound’s potential for addressing hypertension, renal dysfunction, heart failure, and complications related to pregnancy.

Mechanism of Action

B7-33 functions as a selective agonist of RXFP1. By binding to this receptor, it activates intracellular signaling cascades—most notably, the cyclic adenosine monophosphate (cAMP)–protein kinase A (PKA) pathway. This activation promotes vasodilation, reduces vascular resistance, and enhances renal perfusion. Additionally, B7-33 downregulates pro-inflammatory mediators, contributing to improved organ function. The compound mimics physiological actions of relaxin while offering structural advantages that enhance its feasibility for therapeutic use.

Potential Clinical Applications

Hypertension
Experimental models show that B7-33 reduces arterial pressure through RXFP1 activation and cAMP-PKA–mediated vasodilation. Chronic Kidney Disease
Evidence indicates that B7-33 improves renal hemodynamics, decreases inflammatory signaling, and supports filtration efficiency, thereby mitigating progression of renal impairment. Cardiac Insufficiency
In models of heart failure, B7-33 preserved myocardial performance, improved coronary blood flow, and demonstrated anti-inflammatory properties, underscoring its potential role in cardiac care.

Experimental Evidence

Study 1: Post-Myocardial Infarction Outcomes
In murine models of ischemia-reperfusion injury, B7-33 reduced infarct size and enhanced fractional shortening compared with controls. Mechanistically, the compound decreased cardiomyocyte apoptosis, limited endoplasmic reticulum stress, and improved recovery of contractile function. Study 2: Vascular Protective Effects
Comparisons between B7-33 and recombinant relaxin-2 in rat models demonstrated equivalent enhancement of bradykinin-mediated relaxation in mesenteric arteries. Both agents prevented endothelial dysfunction in ex vivo systems simulating preeclampsia, supporting B7-33 as a cost-effective alternative for vascular disease intervention. Study 3: Hyperglycemia-Induced Placental Dysfunction
In cultured human cytotrophoblasts exposed to high glucose concentrations, B7-33 counteracted the anti-angiogenic profile characteristic of preeclampsia. It restored vascular endothelial growth factor (VEGF) expression and activated pro-survival pathways involving mTOR and pAKT, suggesting utility in pregnancy-related vascular complications.

Summary

B7-33 represents a novel RXFP1 agonist with broad therapeutic promise. Preclinical findings highlight its capacity to lower blood pressure, improve renal outcomes, protect myocardium after ischemic injury, and mitigate placental dysfunction associated with preeclampsia. Through selective pathway activation and favorable structural properties, B7-33 may serve as a future treatment option across multiple clinical domains. Continued translational research is warranted to validate these findings in human studies.

REFERENCES

1. Marshall, S. A., O’Sullivan, K., Ng, H. H., Bathgate, R. A. D., Parry, L. J., Hossain, M. A., & Leo, C. H. (2017). B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). European journal of pharmacology, 807, 190–197. https://doi.org/10.1016/j.ejphar.2017.05.005
2. B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice